Lv1
50 积分 2025-12-16 加入
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview
5天前
已关闭
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire
5天前
已完结
医疗机构落实药品集中带量采购政策中的问题及建议
19天前
已关闭
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
22天前
已完结
Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective
22天前
已完结
Stellate ganglion block in perioperative practice: a narrative review
1个月前
已完结
Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review
1个月前
已完结
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
1个月前
已完结
Cutaneous adverse events caused by immune checkpoint inhibitors
1个月前
已完结
皖公网安备34019202002308
